Applied Therapeutics Inc. (APLT) Quarterly EPS earnings growth
Applied Therapeutics (APLT) intellectual property in the US minimizes external risks, while the value of 72.70 aligns with the current metric. The quarterly EPS trend captures the growth rate of earnings per share. A closed system of aldose reductase inhibitors forms the business foundation, while financial potential is based on high-cost orphan drugs for the treatment of galactosemia purchased by insurance funds.
%20Year-over-year%20earnings%20per%20share%20growth%20for%20the%20last%2012%20months&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_APLT_-_Applied-Therapeutics_-_Year-over-year-earnings-per-share-growth-for-the-last-12-months "APLT: appliedtherapeutics.com Year-over-year net earnings per share growth for the last 12 months 07/04/2022 - 02/16/2026 | 👁️GURU.Markets👁️")
Applied Therapeutics Inc. (APLT) - metric breakdowns and financial figures
- share price and expert price forecast:
- market capitalization details:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Capital Applied Therapeutics|APLT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Applied Therapeutics|APLT - Company Aggregate Debts|Debt to Book Capitalization Ratio Applied Therapeutics|APLT - Company Long-Term Loans and Borrowings|Company Short-Term Debt Applied Therapeutics|Quick Ratio appliedtherapeutics.com
- earnings and valuation multiples information:
APLT - Net Profit|Projected Future Earnings Applied Therapeutics|APLT - P/E Multiple|Future Price to Earnings Applied Therapeutics, Inc.|APLT - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Applied Therapeutics|APLT - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Applied Therapeutics|APLT - Earnings per share for the last twelve months|Quarterly EPS earnings growth appliedtherapeutics.com|APLT - Expected net earnings per share growth this year|Earnings growth forecast for next year Applied Therapeutics
Initial company analysis:Applied Therapeutics
To assess the issuer's financial stability, the trend of net income per share is utilized, where quarterly growth measures the pace of business capitalization and cost management efficiency. By analyzing the actual quarterly EPS growth, an investor can see how the monetization of the proprietary aldose reductase inhibitor platform of Applied Therapeutics (APLT) transforms into real income, cementing the company's dominance in the rare metabolic pathology treatment segment.
Who Applied Therapeutics competes with
VRTX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Alnylam Pharmaceuticals, Inc. (ALNY)|INSM (Insmed Inc) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months UTHR (United Therapeutics Inc.)|Year-over-year net earnings per share growth for the last 12 months BMRN (BioMarin Pharmaceutical)|BBIO (bridgebio.com) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months BGM Group BGM|COGT (Cogent Biosciences Inc) - Year-over-year net earnings per share trend for the last twelve months|Xeris Biopharma Inc - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months KROS (Keros Corp)|ARCT: Quarterly EPS earnings growth|etonpharma.com (ETON) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Kamada|FULC: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Abeona Therapeutics (ABEO)|Year-over-year net earnings per share growth for the last 12 months mereobiopharma.com MREO|Quarterly EPS earnings growth PLX (Protalix BioTherapeutics)|Quarterly EPS earnings growth Pliant Therapeutics Inc PLRX|Rein Therapeutics - Quarterly EPS earnings growth|GELS - Quarterly EPS earnings growth|aytubio.com (AYTU) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months CMMB (Chemomab Therapeutics Ltd.)|Year-over-year earnings per share growth for the last twelve months SRx Health Solutions Inc|Polyrizon Ltd. - Year-over-year net earnings per share trend for the last twelve months|Year-over-year earnings per share growth for the last twelve months Aeterna Zentaris (AEZS)|Year-over-year earnings per share growth for the last twelve months CYTH (Cyclo Therapeutics Inc.)|Quarterly EPS earnings growth INZY (Inozyme Pharma)|Year-over-year net earnings per share change for the last twelve months Reneo Pharmaceuticals, Inc (RPHM)|COSCIENS Biopharma Inc. - Quarterly EPS earnings growth
